TP53 and Miyoshi myopathy: A recent RVAS study from Boddicker et al. [8] of 2138 MM cases and 42632 controls found associations between carriers of pathogenic variants in CHEK2 (n = 39, 1.8%) and TP53 (n = 5, 0.2%) and an increased risk of developing MM.